Pharmaceutical Inspection Co-operation Scheme -PIC/S 1/95 (Rev. 7)

📄

Pharmaceutical Inspection Co-operation Scheme (PIC/S 1/95 (Rev. 7))

Publisher: Pharmaceutical Inspection Co-operation Scheme (PIC/S)
Document type: Foundational institutional framework and governing scheme
Publication date: 2 November 2026
Status: Current — in force
Format: PDF, 11 pages (English)

Summary

The Pharmaceutical Inspection Co-operation Scheme (PIC/S 1/95 (Rev. 7)) sets out the institutional framework, mission, membership arrangements and governance of PIC/S. The revised Scheme was adopted by the PIC/S Committee in Istanbul, Türkiye, on 2 November 2026 and entered into force on the same date, replacing the previous revision adopted in November 2019.

The document confirms PIC/S’s status as a non-profit association established under Swiss law and registered in Geneva. Although international in its membership and activities, PIC/S is not an intergovernmental organisation under public international law. The Scheme is a legally non-binding arrangement for cooperation between regulatory authorities and other bodies representing them that are competent to inspect medicinal products in the field of Good Manufacturing Practice (GMP).

Revision 7 places the protection of public health explicitly at the centre of PIC/S’s mission and reinforces cooperation, mutual confidence, GMP inspection reliance and global regulatory convergence. It introduces Participating Organisations as a distinct membership category alongside Participating Authorities, subject to specific PIC/S requirements.

The revised Scheme strengthens the role of the PIC/S Inspectorates’ Academy (PIA) in harmonised inspector training, qualification processes and inspection excellence. It also emphasises structured knowledge transfer, capacity building and the preservation of institutional knowledge across participating inspectorates.

The document clarifies the responsibilities and oversight arrangements of the PIC/S Committee, Executive Bureau and Secretariat. It also updates financial governance provisions, including the conditions under which regular external audits are required under Swiss law. An audit is required when two of the following three thresholds are exceeded for two consecutive financial years: a total balance sheet of CHF 10 million, annual turnover of CHF 20 million, or an average workforce of 50 full-time employees.

Chapter X establishes the framework for sharing confidential information between participating authorities. Information sharing is voluntary and intended to support each authority’s risk management when deciding whether a manufacturing site should be inspected. Shared information is not binding, and the receiving authority is not required to accept another authority’s conclusions. The Scheme also defines categories of information that should not be shared, including commercial and financial data, trade secrets, research information, certain personal data and information that could jeopardise official investigations.

Chapter XI requires a Participating Authority to communicate immediately to the other Participating Authorities any circumstances it identifies that make a medicinal product an imminent and serious danger to the public. The revised Scheme therefore provides an updated institutional basis for international GMP cooperation, inspectorate development and the exchange of regulatory information.

Intended audience

Regulatory authorities and inspectorates participating in or seeking to join PIC/S; pharmaceutical manufacturers and GMP compliance professionals; regulatory affairs and quality assurance specialists; and organisations involved in international GMP inspections, inspection reliance and regulatory cooperation.

POPULAR DOCUMENTS